Christos Christidis
University of Paris
43 Papers
156 Citations
Christos Christidis is an academic researcher from University of Paris. The author has contributed to research in topics: Cirrhosis & Hepatitis C. The author has an hindex of 18, co-authored 41 publications.
Chat about Author
Papers
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis
Laurent Sandrin,Bertrand Fourquet,Jean-Michel Hasquenoph,Sylvain Yon,Céline Fournier,F. Mal,Christos Christidis,Marianne Ziol,Bruno Poulet,Farad Kazemi,Michel Beaugrand,Robert Palau +11 more
TL;DR: Liver elasticity measurements were reproducible, operator-independent and well correlated and the intra- and interoperator reproducibility of the technique, as well as its ability to quantify liver fibrosis, were evaluated in 106 patients with chronic hepatitis C.
2.8K
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C.
Marianne Ziol,Adriana Handra-Luca,Adrien Kettaneh,Christos Christidis,F. Mal,F. Kazemi,Victor de Ledinghen,Patrick Marcellin,Daniel Dhumeaux,Jean-Claude Trinchet,Michel Beaugrand +10 more
TL;DR: Noninvasive assessment of liver stiffness with transient elastography appears as a reliable tool to detect significant fibrosis or cirrhosis in patients with chronic hepatitis C.
1.5K
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
Pierre Nahon,Pierre Nahon,Valérie Bourcier,Richard Layese,Etienne Audureau,Carole Cagnot,Patrick Marcellin,Dominique Guyader,Hélène Fontaine,Dominique Larrey,Victor de Ledinghen,Denis Ouzan,Fabien Zoulim,Dominique Roulot,Albert Tran,Jean-Pierre Bronowicki,Jean-Pierre Zarski,Vincent Leroy,Ghassan Riachi,Paul Calès,Jean-Marie Péron,Laurent Alric,Marc Bourlière,Philippe Mathurin,Sébastien Dharancy,Jean-Frédéric Blanc,Armand Abergel,Lawrence Serfaty,Ariane Mallat,Jean-Didier Grangé,Pierre Attali,Yannick Bacq,Claire Wartelle,Thong Dao,Yves Benhamou,Christophe Pilette,Christine Silvain,Christos Christidis,Dominique Capron,Brigitte Bernard-Chabert,David Zucman,Vincent Di Martino,Vincent Thibaut,Dominique Salmon,Marianne Ziol,Angela Sutton,Stanislas Pol,Françoise Roudot-Thoraval,Gérard Thiéfin,Sophie Hillaire +49 more
TL;DR: A reduction in critical events, liver-related or not, was confirmed in the CirVir cohort, a prospective study of patients with HCV infection and compensated cirrhosis included in the ANRS cohort who achieved an SVR, to reduce overall mortality and risk of death from liver- related and non-liver-related causes.
517
Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death
Françoise Degos,Christos Christidis,Nathalie Ganne-Carrié,J P Farmachidi,Claude Degott,Catherine Guettier,Jean-Claude Trinchet,Michel Beaugrand,Sylvie Chevret +8 more
TL;DR: The incidence of HCC and mortality should be higher in patients with uncomplicated Child-Pugh A HCV related cirrhosis than previously stated, and prognostic factors of H CC and death are closely related age and symptoms of portal hypertension.
398
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs
Pierre Nahon,Pierre Nahon,Richard Layese,Valérie Bourcier,Carole Cagnot,Patrick Marcellin,Dominique Guyader,Stanislas Pol,Dominique Larrey,Victor de Ledinghen,Denis Ouzan,Fabien Zoulim,Dominique Roulot,Albert Tran,Jean-Pierre Bronowicki,Jean-Pierre Zarski,Ghassan Riachi,Paul Calès,Jean-Marie Péron,Laurent Alric,Marc Bourlière,Philippe Mathurin,Jean-Frédéric Blanc,Armand Abergel,Lawrence Serfaty,Ariane Mallat,Jean-Didier Grangé,Pierre Attali,Yannick Bacq,Claire Wartelle,Thong Dao,Dominique Thabut,Christophe Pilette,Christine Silvain,Christos Christidis,Eric Nguyen-Khac,Brigitte Bernard-Chabert,David Zucman,Vincent Di Martino,Angela Sutton,Françoise Roudot-Thoraval,Etienne Audureau,Hélène Fontaine,Vincent Leroy,Sébastien Dharancy,Sophie Hillaire +45 more
TL;DR: Analysis of data from the ANRS CO12 CirVir cohort reveals that the apparent increase in HCC incidence observed in patients with cirrhosis treated with DAAs compared with patients who achieved SVR following an IFN therapy can be explained by patient characteristics (age, diabetes, reduced liver function) and lower screening intensity.
218